Mit Magzter GOLD unbegrenztes Potenzial nutzen

Mit Magzter GOLD unbegrenztes Potenzial nutzen

Erhalten Sie unbegrenzten Zugriff auf über 9.000 Zeitschriften, Zeitungen und Premium-Artikel für nur

$149.99
 
$74.99/Jahr
The Perfect Holiday Gift Gift Now

PCI to continue as a high-level professional standard setting body

Chronicle Pharmabiz

|

January 1, 2026

Following the landmark decision to retain the Pharmacy Council of India's (PCI) independent status under the Viksit Bharat Shiksha Adhishthan (VBSA) Bill, 2025, the legislation unveils a sophisticated new architecture for the profession.

- Peethaambaran, Chennai

This second phase of reform transitions the PCI from a traditional regulator into a high-level Professional Standard Setting Body (PSSB). This evolution ensures that while the Council moves away from direct administrative management of institutions, it gains unparalleled authority over the academic and clinical benchmarks of the discipline.

WEITERE GESCHICHTEN VON Chronicle Pharmabiz

Chronicle Pharmabiz

Telangana DCA busts unlicensed medical device unit in Sangareddy

IN a major enforcement action, the DCA of Telangana busted an unlicensed medical device manufacturing facility in Sangareddy District on December 23, 2025.

time to read

1 mins

January 1, 2026

Chronicle Pharmabiz

Motilal Oswal invests US$ 72 mn in Sensa Core

MOTILAL Oswal Alternates had Monde Oswal AlternatES made a significant minority investment of US$ 72 million in Sensa Core, an innovation-driven medical devices' company focused on advancing healthcare technology in India.

time to read

1 mins

January 1, 2026

Chronicle Pharmabiz

Odisha announces Pharma, Med Devices Policy 2025

MARKING a historic shift in the state's industrial landscape, chief minister Mohan Charan Majhi has officially unveiled the Odisha Pharmaceutical and Medical Devices Policy 2025 at the inaugural Odisha Pharma Summit in Bhubaneswar on December 16.

time to read

1 min

January 1, 2026

Chronicle Pharmabiz

Experts highlight policy intervention in pricing reforms

PRICING reforms must balance affordability with industry viability. Rational, transparent pricing models, volume-forprice contracts, and tiered pricing for non-essential therapies can sustain manufacturer participation going forward, highlights Dr Kunal Saxena, managing director, Rusan Pharma Ltd.

time to read

1 min

January 1, 2026

Chronicle Pharmabiz

Glenmark launches epinephrine in US market

GLENMARK PharmaceutiGcals Inc, USA (Glenmark) Glenannounced the launch of epinephrine injection USP, 30 mg/30 mL (1 mg/mL) multiple-dose vial.

time to read

1 min

January 1, 2026

Chronicle Pharmabiz

SSSIHMS, Siemens Healthineers ink research pact

SHRI Sathya Sai Institute of Higher Medical Sciences (SSSIHMS) and Siemens Healthineers have entered a strategic clinical research collaboration titled, 'Collaborative Clinical Research in Echocardiography.'

time to read

1 min

January 1, 2026

Chronicle Pharmabiz

PCI to continue as a high-level professional standard setting body

Following the landmark decision to retain the Pharmacy Council of India's (PCI) independent status under the Viksit Bharat Shiksha Adhishthan (VBSA) Bill, 2025, the legislation unveils a sophisticated new architecture for the profession.

time to read

1 mins

January 1, 2026

Chronicle Pharmabiz

Pondicherry refers multi-crore counterfeit medicine racket to CBI

As the Government of Pondicherry has officially handed over the massive counterfeit medicine scandal to the Central Bureau of Investigation (CBI) and the National Investigation Agency (NIA), the focus of the probe is shifting from the initial arrests to a series of alarming, unanswered questions.

time to read

1 mins

January 1, 2026

Chronicle Pharmabiz

AFDLHF announces boycott of MMGPA tender

THE All Food and Drug Licence Holders Foundation (AFDLHF) has announced a complete boycott of the Maharashtra Medical Goods Authority (MMGPA) tender process, citing serious concerns over the introduction of an unlawful and anti-competitive \"Bunch Bid\" clause impacting Pharma Micro, Small and Medium Enterprises (MSMEs).

time to read

1 mins

January 1, 2026

Chronicle Pharmabiz

Daiichi Sankyo & AstraZeneca's Enhertu approved in China

ENHERTU (trastuzumab deruxtecan) has been approved China for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 low (IHC 1+ or IHC 2+/ISH-) or HER2 ultralow (IHC 0 with membrane staining) breast cancer that has progressed on one or more endocrine therapies in the metastatic setting.

time to read

1 mins

January 1, 2026

Listen

Translate

Share

-
+

Change font size

Holiday offer front
Holiday offer back